Janet Harris-Hicks, MD
Urogynecology and Reconstructive Pelvic Surgery · Myrtle Beach, SCNPI 1225125669
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (36.3%), education and travel and lodging — rather than concentrated in one kind of arrangement. Coloplast accounts for 81.2% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $91,670 and has fallen 51.2% since, to $44,697 in 2025.
Across 516 payments — averaging $548.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$230K
- Medtronic$31K
- Intuitive Surgical$11K
- Axonics, Inc.$3K
- Sumitomo Pharma America, Inc.$3K
- Escala Medical Inc.$1K
- plus $3K from 17 others
Across 72 payments — averaging $7792.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$332K
- Coloplast$166K
- AbbVie$31K
- Boston Scientific$22K
- Sumitomo Pharma America, Inc.$9K
What the payments were for
- Consulting fees$102,76236%
- Speaking & faculty fees$17,9006%
- Travel & lodging$50,31818%
- Food & beverage$12,6814%
- Education$99,50935%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 284 | $229,956 |
| Medtronic(2 entities) | 84 | $31,250 |
| Intuitive Surgical | 28 | $11,353 |
| Axonics, Inc. | 27 | $3,357 |
| Sumitomo Pharma America, Inc. | 8 | $2,838 |
| Escala Medical Inc. | 3 | $1,011 |
| Minze Health, Inc | 2 | $903 |
| Astellas Pharma US Inc | 27 | $732 |
| AbbVie(2 entities) | 22 | $634 |
| Teleflex LLC | 3 | $384 |
| Femselect Inc. | 2 | $123 |
| Boston Scientific | 2 | $121 |
| Pfizer | 6 | $100 |
| Neuraxis, Inc. | 1 | $81 |
| Laborie Medical Technologies Corp. | 3 | $73 |
| Novo Nordisk | 3 | $56 |
| Therapeuticsmd, Inc. | 2 | $42 |
| Ascend Therapeutics US, LLC | 2 | $35 |
| AMAG Pharmaceuticals, Inc. | 2 | $31 |
| Urovant Sciences Inc | 2 | $30 |
| Myovant Sciences Inc. | 1 | $25 |
| Ambu Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTIS$214,439
- DAVINCI XI$9,000
- RESTORELLE$8,063
- INTERSTIM$7,783
- Axonics$2,696
- GEMTESA$2,678
- Da Vinci Surgical System$1,948
- TITAN$1,339
- AXIS$1,261
- Minze Homeflow$825
- ALTAVIVA$751
- STRAIGHTSHOT$570
- Barrigel$350
- BOTOX COSMETIC$136
- Bulkamid$118
How this compares
Too few urogynecology and reconstructive pelvic surgery providers in South Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 89 | $49,633 |
| GemtesaVibegron | 56 | $42,664 |
| Estradiol | 271 | $14,337 |
| PremarinEstrogens, Conjugated | 21 | $8,957 |
| YuvafemEstradiol | 20 | $1,797 |
| Tamsulosin Hcl | 139 | $1,178 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 108 | $1,130 |
| Bethanechol Chloride | 16 | $1,041 |
| Np ThyroidThyroid,pork | 17 | $667 |
| NitrofurantoinNitrofurantoin Macrocrystal | 38 | $394 |
| Cephalexin | 93 | $363 |
| Clobetasol Propionate | 31 | $322 |
| ValacyclovirValacyclovir Hcl | 14 | $218 |
| Ciprofloxacin Hcl | 16 | $118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $732 | $49,63389 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $2,838 | $42,66456 claims |
| PfizerPremarin | $100 | $8,95721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in South Carolinaon file to place this against a meaningful peer group, so we don't.
Other urogynecology and reconstructive pelvic surgery in Myrtle Beach
- Thomas GiudiceWest Columbia$418K
- Eric RovnerCharleston$284K
- Jessica RuebWest Columbia$12K
- Rebecca RinkoGreenville$9K
- Ronald GlinskiFlorence$8K
- Gerald TaylorCharleston$7K
- Thomas WheelerSpartanburg$6K
- Collin McKenzieWest Columbia$6K
- Johnnie WrightColumbia$4K
- Haley McEvoyMount Pleasant$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.